SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR

Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug biosimilar provides a reduction in the cost of the...

Full description

Saved in:
Bibliographic Details
Main Authors: A. N. Afanasyeva, V. B. Saparova, D. D. Karal-Ogly, E. I. Mukhametzyanova, D. V. Kurkin, A. V. Kalatanova, I. E. Makarenko, A. L. Khokhlov, I. A. Lugovik
Format: Article
Language:Russian
Published: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2022-10-01
Series:Фармация и фармакология (Пятигорск)
Subjects:
romiplostim
biosimilar gp40141
nplate®
complement-dependent cytotoxicity
drug safety studies
in vivo
in vitro
idiopathic thrombocytopenic purpura
toxicological profile
thrombopoietin receptor
tpo-r
Online Access:https://www.pharmpharm.ru/jour/article/view/1165
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.pharmpharm.ru/jour/article/view/1165

Similar Items